| Name | Title | Contact Details |
|---|
Engineering next‑generation, brain‑penetrant cancer therapies.
We are dedicated to developing lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.
Xpention Genetics Inc is a Conifer, CO-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.
TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.